Synopsis
Oncology Pharmacist & Educator. Talking all things #oncopharm
Episodes
-
Antiandrogen Withdrawal
25/06/2025 Duration: 09minAntiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?
-
June 2025 Updates
19/06/2025 Duration: 27minA plethora of recent updates: -Pembrolizumab (perioperative) in head & neck cancer (Keynote-689) -Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib -Pirtobrutinib improves PFS in CLL -Zanubrutinib has a new dosage form on the way -Another mitomycin product approved with "reverse thermal properties" -A new regimen for FL of tafasitamab/rituximab/lenalidomide -A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options
-
Talking about cancer misinformation
22/05/2025 Duration: 15minIf you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you. 1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857 2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526
-
Four New Drugs
22/05/2025 Duration: 12minDiscussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.
-
Mg to Prevent Cisplatin Kidney Injury
08/05/2025 Duration: 15minA splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury. Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756 PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351 Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/
-
TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
01/05/2025 Duration: 12minThis episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
-
BRCA Reversion Mutations
24/04/2025 Duration: 12minBRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors. Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015
-
HOPA 25 Recap
17/04/2025 Duration: 11minRecapping HOPA 25 and Portland *Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!
-
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
08/04/2025 Duration: 12minFDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
-
API-CAT & IMPROVE
03/04/2025 Duration: 12minWe discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)
-
Keynote 811 Update
19/03/2025 Duration: 12minThe updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.
-
Polar: Cryotherapy or Compression to Prevent Taxane-induced neuropathy
13/03/2025 Duration: 09minThere is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR. POLAR: doi:10.1001/jamaoncol.2025.0001
-
About Herb Drug Interactions
06/03/2025 Duration: 11minTen of the top herb-chemotherapy interactions. About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search Also, search 'About Herbs' in your app store.
-
Rethinking Premeds
27/02/2025 Duration: 08minTwo recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time! Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158 Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470 We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
-
OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T
13/02/2025 Duration: 12minMorbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports. 1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2. CD4+ T-cell lymphoma harboring a CAR integration into TP53: https://www.nejm.org/doi/full/10.1056/NEJMoa2411507
-
[Re-release] Rituximab
06/02/2025 Duration: 18minDipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?